Interestingly, in this patient subgroup, the IFN-γ/IL-17F ratio discriminated CIS from MS and RRMS more accurately than IL-17F alone, supporting the notion that in some cases, the ratio between cytokines rather than individual cytokines might better reflect disease progression. This evidence concerns the gene IL17F and in situ carcinoma.